Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
Chen S-Y, Yu H-T, Kao J-P, Yang C-C, Chiang S-S, Mishchuk DO, et al
Agrawal recommends discussing: All medications youre taking, especially those that may increase hypoglycemia risk Your typical drinking habits and frequency Any history of pancreatitis, liver disease, or heavy alcohol use Whether nausea, vomiting, or severe hangovers have already occurred on the medication How to recognize and treat low blood sugar if it happens while drinking These discussions allow providers to give individualized advice instead of generic warnings, Agrawal says
Intrinsic Mechanisms An increased level of oxidative stress caused by low levels of heme oxygenase-1 (HO-1) is associated with DGp in experimental models
-Can increase development of lean body mass -May reduce body fat through lipolysis